Hu-manity.co and IBM Partner for Personal Data Property Rights
Hu-manity.co, the organization developing human rights and corollary sovereign laws in a decentralized manner on blockchains, announced it will use IBM’s Blockchain Platform technology for its global consent ledger. Using IBM’s platform, Hu-manity.co will give people control to manage consent, authorization, and commercial use of their personal information via a permissioned blockchain-based data marketplace.
Consumers can claim their human data rights via Hu-manity.co’s #My31 iPhone and Android app built on IBM Blockchain. Some capabilities include users can choose to share no information with third parties, or they may want to provide consent for use of their medical data for cancer research only. Users can also choose to lease their data to pharmaceutical companies or data aggregators but only upon receiving fair market compensation.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
